Two women are being added to the board of directors at GlaxoSmithKline (NYSE: GSK).
The British government has recently raised concerns about the lack of female board members at UK firms, according to the London Evening Standard. The newspaper quoted a GSK insider as saying the board moves at GSK were “coincidental.”
Joining the board as of Apirl 1 are Judy Lewent, a former chief financial officer at Merck, and Stacey Cartwright, CFO at Burberry Group.
Their additions will mean three of GSK’s board spots are held by woman, which would be a new high, according to the Standard.
Read the Standard story here.
GSK operates its US headquarters in RTP.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.